Marc Carrier/X
Aug 31, 2025, 07:23
Extended Low-Dose Apixaban After Provoked VTE: Marc Carrier Spotlights Major NEJM Results
Marc Carrier, Professor at Ottawa Hospital Research Institute, has posted on X:
”New in NEJM:
In patients with provoked VTE + enduring risk factors, extended low-dose apixaban (2.5 mg bid ×12 months): reduced recurrent VTE risk by nearly 90% (1.3% vs 10.0%): HR 0.13
Major bleeding was rare (1 pt).”
Find the full study here.
Title: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Authors: Gregory Piazza, Behnood Bikdeli, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison, Heather Hogan, Sina Rashedi, Mariana Pfeferman, Junyang Lou, John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, and Samuel Z. Goldhaber
Stay updated with Hemostasis Today.
Antoine Bejjani
Apixaban
Arvind K. Pandey
Behnood Bikdeli
Bleeding Risk
Brigham and Women’s Hospital–Harvard Medical School
Candrika D Khairani
Darsiya Krishnathasan
Direct Oral Anticoagulants
DOAC
eth Israel Deaconess Medical Center
Gregory Piazza
Health
Heather Hogan
Hematology
Hemostasis
Hemostasis Today
HI-PRO trial
John Fanikos
Junyang Lou
Lisa Rosenbaum
Marc Carrier
Mariana Pfeferman
Marie Gerhard-Herman
Medicine
NEJM
Nicole Porio
Ottawa Hospital Research Institute
Piotr Sobieszczyk
provoked venous thromboembolism
Recurrent VTE
Ruth H. Morrison
Samuel Z. Goldhaber
Sina Rashedi
The New England Journal of Medicine
thrombosis
Umberto Campia
University of Pittsburgh Medical Center
venous thromboembolism
Venous Thrombosis
VTE
Yale Center for Outcomes Research and Evaluation
Zhou Lan
-
Oct 21, 2025, 05:20Ewa Fiorentino Rozek: APS - When “Unprovoked” Clots And Pregnancy Loss Connect
-
Oct 21, 2025, 03:503 Questions With Abigail Ajanel Gomez – Touch Haematology Future Leader 2025
-
Oct 21, 2025, 01:57Mohamed Reda: Clotting Factors — The Key Players in Blood Coagulation
-
Oct 20, 2025, 13:23From Words to Action: David McIntosh Advocates for Investment in Lifesaving Maternal Care
-
Oct 20, 2025, 13:21Royal College of Physicians of Edinburgh: Haematology 2025 — Presentation, Prevention and Possibilities
-
Oct 21, 2025, 11:13Hanny Al Samkari's Commentary on Iron Deficiency Anemia in Inherited Bleeding Disorders
-
Oct 21, 2025, 11:08Wolfgang Miesbach on New Real-World Data for Haemophilia B Prophylaxis
-
Oct 21, 2025, 05:54John Strouse on Hydroxyurea for Children with Sickle Cell Disease
-
Oct 20, 2025, 13:22Saleh Shamse Basha Shared New Interesting Clinical Case With Recurrent Nosebleeds and Prolonged Bleeding After Dental Extractions
-
Oct 20, 2025, 13:19Steven AR Murphy: Platelet Rich Plasma is a Regenerative Therapy
-
Oct 21, 2025, 06:18Katerina Akassoglou Receives Zenith Fellows Award to Advance Alzheimer’s Research
-
Oct 16, 2025, 06:07ClearPlasma - A New Breakthrough in Stopping Life-Threatening Bleeds
-
Oct 14, 2025, 05:26Ryan C. Heniford: Every Thrombus Prevented Is a Patient Protected
-
Oct 13, 2025, 04:48Archil Jaliashvili showcases how BHOC builds on Hemopure’s success to revolutionize surgery and care
-
Oct 13, 2025, 02:46Flora Peyvandi: First Proposed Blood Test for Chronic Fatigue Syndrome - What Scientists Think
-
Oct 21, 2025, 11:11Nana Kwame Kwabi Boateng: Grateful For The Opportunity to Serve As A SEARCH Ambassador
-
Oct 21, 2025, 05:00Sheila Cristina Ouriques Martins Is Grateful to Be Among The Legends Who Changed The Reality of Stroke Worldwide
-
Oct 21, 2025, 01:47Cathy Bliem: Yesterday, I Made My 4th Plasma Donation of 2025...
-
Oct 20, 2025, 12:40Asfand Yar Cheema: Honored to be featured in Video Journal of Hematology and Hematological Oncology
-
Oct 20, 2025, 12:25Laurent Bertoletti Highlights Evolving Role of Anticoagulation in Pulmonary Hypertension Treatment
Oct 21, 2025, 11:08
Oct 21, 2025, 05:54
Oct 21, 2025, 03:50
Oct 21, 2025, 01:57
Oct 21, 2025, 01:47